J&J asks court for quick decision in 340B rebate model fight
Johnson & Johnson has asked a federal district court to expedite its decision in a case over the company’s proposed 340B rebate model, citing upcoming deadlines for complying with the Inflation...
View ArticleAmgen announces hold on Phase 1 obesity candidate, pipeline cuts
Amgen said one of its early-stage obesity programs has been put on a clinical hold by the FDA, while reiterating its ambitions to become a major player in the crowded field. The company hasn’t revealed...
View ArticleUpdated: Novo Nordisk sees growth slowing this year, plans CagriSema filing...
Novo Nordisk had a good 2024, but this year might be less stellar. The Danish company’s 2024 sales increased 26% from the year before at constant currency, it said Wednesday, but ...
View ArticleGSK defiant against vaccine challenges, will prioritize other growth areas
GSK said it is holding steady in the face of ongoing regulatory and potential political pressures on its vaccines franchise, which saw full-year 2024 sales slide from the year prior. The drop was...
View ArticleWith first drug now in the clinic, Alys eyes megaround for rest of pipeline
Alys Pharmaceuticals is on the hunt for a large financing to carry forward its pipeline — an amalgamation of six Medicxi startups — following the clearance of its first clinical trial this week ...
View ArticleEyePoint shares more mid-stage data for therapy trying to compete with...
EyePoint Pharmaceuticals, a biotech attempting to grab a sliver of Regeneron's share of the degenerative eye disease market, said six-month results show its drug met the primary endpoint in a Phase 2...
View ArticleBristol Myers, Kyowa Kirin disclose layoffs
Bristol Myers Squibb lays off 67 staffers in NJ: The company is letting go of 67 workers in Lawrence Township between April and December, according to a New Jersey WARN Notice ...
View ArticleRevance, Crown near deal close after earlier bidding war
The fight over who gets control of Revance Therapeutics and its Botox competitor, Daxxify, is coming to a close. On Wednesday, Revance said it’s moving forward with its sale to Crown Laboratories. The...
View ArticleSmall personalized vaccine trial sees progress in late-stage kidney cancer
All nine late-stage kidney cancer patients in a Phase 1 trial of a personalized vaccine remained cancer-free after about three years of receiving treatment, researchers wrote in a Nature paper
View ArticleNovo Nordisk is feeling the competition from compounded GLP-1s, exec says
Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That competition is cutting into demand for Novo Nordisk’s prescriptions, a...
View ArticleKura's AML drug succeeds in advanced patients, will take to FDA
The race is on between Kura Oncology and Syndax Pharmaceuticals. On Wednesday, Kura and its partner Kyowa Kirin announced that their targeted treatment ziftomenib succeeded in a key study for a subset...
View ArticleTeladoc to buy Catapult Health for $65M
Teladoc said it will buy at-home testing company Catapult Health for $65 million on Wednesday as it continues to steer its business away from BetterHelp into its other longer-term care programs....
View ArticleBristol Myers launches new round of major cost cuts
Less than a year after announcing a major cost-cutting campaign, Bristol Myers Squibb is planning another round that will be even larger. On Thursday, the company said it plans to find $2 billion in...
View ArticleLilly posts 45% sales jump, culls four programs across obesity, Alzheimer's,...
Eli Lilly said Thursday that its fourth-quarter revenue jumped 45% to $13.53 billion over the prior year, though this fell short of earlier projections. The drugmaker also reiterated the $58 billion to...
View ArticleAstraZeneca offers some detail on China probe, reaffirms commitment to that...
LONDON — AstraZeneca on Thursday provided insight on an ongoing China probe into the company concerning alleged illegal drug imports, giving investors and analysts some reassurance on the pharma...
View ArticlePersonify Health shares 2024 revenue, profitability
Personify Health, which sells healthcare spending management services to employers, has reached more than half a billion dollars in revenue following the 2023 merger that created the current business....
View ArticlePfizer hires Novartis oncology exec to steer its cancer ambitions
After promoting its oncology officer Chris Boshoff to chief scientific officer last fall, Pfizer has found his successor. Jeff Legos, the global head of oncology at Novartis — which has scored multiple...
View ArticleAffyImmune’s layoffs; Henlius makes a biosimilar deal with Dr. Reddy’s
Plus, news about X4 Pharmaceuticals, Viracta Therapeutics, Crown Laboratories, Qlaris and Hitachi. AffyImmune’s layoffs: The CAR-T biotech went through a round of layoffs and restructuring last month,...
View ArticleJ&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying...
It took one month for Johnson & Johnson to secure its $14 billion acquisition of Intra-Cellular Therapies, according to new securities filings that shed light into the back-and-forth talks behind...
View ArticleAstraZeneca takes $753M charge on abandoned complement drug from Alexion deal
AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for Alexion in 2021. The UK major recorded an impairment charge of $753 million as a...
View Article